TACE联合索拉非尼治疗中晚期肝细胞肝癌疗效及安全性初步评价

TACE combined with sorafenib in the treatment of advanced HCC preliminary evaluation of the efficacy and safety

目的探讨明胶海绵微粒(GSMs)肝动脉化疗栓塞(TACE)联合索拉非尼治疗中晚期肝细胞癌(HCC)的疗效和安全性。方法回顾性分析中晚期肝癌患者应用明胶海绵微粒肝动脉化疗栓塞联合索拉非尼治疗17例,每4～8周为一个疗程,根据mRECIST标准进行疗效评价,评价指标为患者的总生存时间(OS)及致疾病进展时间(TTP),并记录不良事件。使用SPSS 19.0软件对病人建立临床资料档案,通过入院治疗评价或门诊及电话方式进行随访,并对结果进行分析。统计方法包括:所有生存率采用寿命表法,所有生存率曲线均采用Kaplan-Meier法,对生存率之间的比较采用Log-rank法检验等。结果GSMs-TACE联合索拉非尼治疗:中位生存时间为(mOS)(34. 73±4. 81)个月(95%CI:25.30～44. 16),中位致疾病进展时间(mTTP) 9.5个月(95%EI, 5.87～13.13);主要毒性反应:手足皮肤反应(61.1%)及高血压(55.6%)。结论GSMs-TACE联合索拉非尼治疗不能手术切除的中晚期肝细胞癌患者耐受性良好,安全,存在与索拉非尼相关的毒副反应。

Objective Explore the gelatin sponge particles( GSMs) transcatheter hepatic arterial chemoembolization(TACE) combined with the efficacy and safety of sorafenib in the treatment of advanced hepatocellular carcinoma(HCC). Methods A retrospective analysis of 17 cases of patients with advanced hepatocellular carcinoma, all patients receivedgelatin sponge particles hepatic artery chemoembolization combined with sorafenib treatment. Every four to eight weeks for a course of treatment, Evaluation mRECIST standard, Evaluation for the patient’s overall survival(OS) and cause time to disease progression(TTP), and recorded adverse events. Use the the SPSS 19. Osoftware on 54 patients to establish clinical data files, hospital treatment evaluation or outpatient and telephone followup, and analyze the results. Statistical methods included: all survival rates using the life table method, all survival curves using the Kaplan-Meier method, on the survival rates between the Log-rank method was used to compare the test. Results GSMs-TACE combined with sorafenib treatment: median survival time(mOS) 34. 73 ±4. 81 months(95% CI: 25. 30 ~ 44. 16),median time to disease progression(mTTP) 9. 5 caused(95% El: 5. 87 ~ 13. 13);the main toxicity: hand-foot skin reaction(61. 1%) and hypertension(55. 6%).Conclusion GSMs-TACE combined with sorafenib treatment of unresectable advanced hepatocellular carcinoma in patients with welltolerated, safe, presence of sorafenib-related toxicity.